Does mefloquine prophylaxis affect electroencephalographic patterns? (Q42165022)

17 October 2017

title

Does mefloquine prophylaxis affect electroencephalographic patterns? (English)

1 reference

17 October 2017

main subject

electroencephalography

1 reference

1 reference

Eli Schwartz

1 reference

17 October 2017

Israel Potasman

1 reference

17 October 2017

Yoav Juven

series ordinal

1 reference

17 October 2017

Boaz Weller

series ordinal

1 reference

17 October 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

American Journal of Medicine

17 October 2017

published in

1 reference

17 October 2017

volume

112

1 reference

17 October 2017

1 reference

17 October 2017

page(s)

147-149

1 reference

Mefloquine for malaria chemoprophylaxis 1992-1998: a review.

17 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Long-term malaria prophylaxis with weekly mefloquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Neuropsychiatric side effects after the use of mefloquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Neuropsychiatric reactions with mefloquine chemoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

CNS adverse events associated with antimalarial agents. Fact or fiction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Mefloquine, Methodologies, and the Media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Determination of primaquine in biological fluids by reversed-phase high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Seizure associated with olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Epileptogenic effect of antibiotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Neurotoxicity of β-lactam antibiotics: predisposing factors and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Lack of bioequivalence of a generic mefloquine tablet with the standard product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Convulsions associated with prophylactic antimalarial drugs: implications for people with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Chloroquine seizures. Report of four cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Does chloroquine cause seizures? Presentation of three new cases and a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

User Acceptability Patterns for Mefloquine and Doxycycline Malaria Chemoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2901065-8

10.1016/S0002-9343(01)01065-8

7 January 2021

Identifiers

DOI

1 reference

17 October 2017

1 reference